Stereotactic body radiation therapy for liver primary and metastases: the Lille experience

The CyberKnife(®) system is a recent radiation therapy technique that allows treatment of liver lesions with real-time tracking. Because of its high precision, the dose administered to the tumor can be increased. We report Oscar-Lambret Cancer Centre experience in the treatment of primary and second...

Full description

Saved in:
Bibliographic Details
Published in:Cancer radiothérapie 2012-02, Vol.16 (1), p.58
Main Authors: Dewas, S, Mirabel, X, Kramar, A, Jarraya, H, Lacornerie, T, Dewas-Vautravers, C, Fumagalli, I, Lartigau, É
Format: Article
Language:fre
Subjects:
Adult
Aged
Aged, 80 and over
Bile Duct Neoplasms - mortality
Bile Duct Neoplasms - surgery
Carcinoma, Hepatocellular - mortality
Carcinoma, Hepatocellular - secondary
Carcinoma, Hepatocellular - surgery
Cholangiocarcinoma - mortality
Cholangiocarcinoma - surgery
Female
France
Humans
Liver Neoplasms - mortality
Liver Neoplasms - secondary
Liver Neoplasms - surgery
Male
Middle Aged
Neoplasm Recurrence, Local
Radiosurgery - adverse effects
Radiosurgery - methods
Radiotherapy Dosage
Retrospective Studies
Young Adult
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The CyberKnife(®) system is a recent radiation therapy technique that allows treatment of liver lesions with real-time tracking. Because of its high precision, the dose administered to the tumor can be increased. We report Oscar-Lambret Cancer Centre experience in the treatment of primary and secondary liver lesions. It is a retrospective study analyzing all the patients who have been treated for their liver lesions since July 2007. A hundred and twenty patients have been treated: 42 for hepatocellular carcinoma, 72 for liver metastases and six for cholangiocarcinoma. Gold seeds need to be implanted before the treatment and are used as markers to follow the movement of the lesion due to respiration. On average, the treatment is administered in three to four sessions over 12 days. A total dose of 40 to 45 Gy at the 80% isodose is delivered. Local control and overall survival analysis with Log-rank is performed for each type of lesion. Treatment tolerance is good. The most common toxicities are of digestive type, pain and asthenia. Six gastro-duodenal ulcers and two radiation-induced liver disease (RILD) were observed. At a median follow-up of 15 months, the local control rate is respectively of 80.4% and 72.5% at 1 and 2 years. Overall survival is 84.6 and 58.3% at 1 and 2 years. The local control is significantly better for the hepatocellular carcinoma and overall survival is significantly better for liver metastases (P
ISSN:1769-6658
DOI:10.1016/j.canrad.2011.06.005